Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Nov;85(11):1640–1645. doi: 10.1054/bjoc.2001.2152

Continuous angiotensin II infusion increases tumour: normal blood flow ratio in colo-rectal liver metastases

D Burke 1, M M Davies 1, J Zweit 2, M A Flower 2, R J Ott 2, M J Dworkin 1, C Glover 1, V R McCready 2, P Carnochan 2, T G Allen-Mersh 1
PMCID: PMC2363967  PMID: 11742481

Abstract

Insufficient blood flow within colo-rectal hepatic metastases is a factor which may limit drug delivery to, and thus the response of, these tumours to regional chemotherapy. Loco-regional flow may be manipulated pharmacologically to enhance the tumour blood flow relative to that of the normal liver. However, as yet, only transient effects have been studied. Patients receiving regional chemotherapy for unresectable hepatic disease were given a 45 min regional infusion of the vasoconstrictor Angiotensin II. Intrahepatic blood flow distribution was assessed serially by Positron Emission Tomography (PET) imaging together with the trapping tracer copper(II) pyruvaldehyde bis(N-4-methylthiosemicarbazone) (Cu-PTSM) labelled using copper-62. Eleven lesions in nine patients were studied, with no adverse effects. Prior to Angiotensin II administration tumour blood flow was generally found to be greater than that of liver (10/11 lesions; 8/9 patients; median TNR 1.3, iqr 0.9–2.5). A significant increase in relative flow to tumour was seen in response to 10 min Angiotensin II infusion in most cases (7/11 lesions; 7/9 patients; median TNR 2.1, iqr 1.4–4.1; P = 0.008), which appeared to be sustained throughout the 45 min infusion period (median TNR 1.85, iqr 1.3–3.8; P = 0.03). These effects were accompanied by transient elevation of mean arterial pressure, but no change in pulse rate. These observations suggest that prolonged regional vasoconstrictor administration could prove useful in the management of unresectable colo-rectal hepatic metastases, and that further development of vascular manipulation to enhance tumour targeting and drug delivery is warranted. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: colo-rectal liver metastases, Angiotensin II, PET, blood flow, 62Cu-PTSM

Full Text

The Full Text of this article is available as a PDF (74.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ackerman N. B. The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery. 1974 Apr;75(4):589–596. [PubMed] [Google Scholar]
  2. Allen-Mersh T. G., Earlam S., Fordy C., Abrams K., Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet. 1994 Nov 5;344(8932):1255–1260. doi: 10.1016/s0140-6736(94)90750-1. [DOI] [PubMed] [Google Scholar]
  3. Ashraf S., Loizidou M., Crowe R., Turmaine M., Taylor I., Burnstock G. Blood vessels in liver metastases from both sarcoma and carcinoma lack perivascular innervation and smooth muscle cells. Clin Exp Metastasis. 1997 Sep;15(5):484–498. doi: 10.1023/a:1018466608614. [DOI] [PubMed] [Google Scholar]
  4. Daly J. M., Butler J., Kemeny N., Yeh S. D., Ridge J. A., Botet J., Bading J. R., DeCosse J. J., Benua R. S. Predicting tumor response in patients with colorectal hepatic metastases. Ann Surg. 1985 Sep;202(3):384–393. doi: 10.1097/00000658-198509000-00017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dimitrakopoulou-Strauss A., Strauss L. G., Schlag P., Hohenberger P., Irngartinger G., Oberdorfer F., Doll J., van Kaick G. Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma. J Nucl Med. 1998 Mar;39(3):465–473. [PubMed] [Google Scholar]
  6. Dworkin M. J., Carnochan P., Allen-Mersh T. G. Effect of continuous regional vasoactive agent infusion on liver metastasis blood flow. Br J Cancer. 1997;76(9):1205–1210. doi: 10.1038/bjc.1997.534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dworkin M. J., Carnochan P., Allen-Mersh T. G. Nitric oxide inhibition sustains vasopressin-induced vasoconstriction. Br J Cancer. 1995 May;71(5):942–944. doi: 10.1038/bjc.1995.182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Flower M. A., Zweit J., Hall A. D., Burke D., Davies M. M., Dworkin M. J., Young H. E., Mundy J., Ott R. J., McCready V. R. 62Cu-PTSM and PET used for the assessment of angiotensin II-induced blood flow changes in patients with colorectal liver metastases. Eur J Nucl Med. 2001 Jan;28(1):99–103. doi: 10.1007/s002590000410. [DOI] [PubMed] [Google Scholar]
  9. Goldberg J. A., Thomson J. A., Bradnam M. S., Fenner J., Bessent R. G., McKillop J. H., Kerr D. J., McArdle C. S. Angiotensin II as a potential method of targeting cytotoxic-loaded microspheres in patients with colorectal liver metastases. Br J Cancer. 1991 Jul;64(1):114–119. doi: 10.1038/bjc.1991.252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hafström L., Nobin A., Persson B., Sundqvist K. Effects of catecholamines on cardiovascular response and blood flow distribution to normal tissue and liver tumors in rats. Cancer Res. 1980 Feb;40(2):481–485. [PubMed] [Google Scholar]
  11. Hemingway D. M., Angerson W. J., Anderson J. H., Goldberg J. A., McArdle C. S., Cooke T. G. Monitoring blood flow to colorectal liver metastases using laser Doppler flowmetry: the effect of angiotensin II. Br J Cancer. 1992 Nov;66(5):958–960. doi: 10.1038/bjc.1992.392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hennigan T. W., Earlam S., Allen-Mersh T. G. Is liver to lung shunting in colorectal liver metastasis the cause of toxicity following treatment with cytotoxic microsphere aggregates? Br J Cancer. 1992 Dec;66(6):1169–1170. doi: 10.1038/bjc.1992.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Marsden P. K., Ott R. J., Bateman J. E., Cherry S. R., Flower M. A., Webb S. The performance of a multiwire proportional chamber positron camera for clinical use. Phys Med Biol. 1989 Aug;34(8):1043–1062. doi: 10.1088/0031-9155/34/8/007. [DOI] [PubMed] [Google Scholar]
  14. Mathias C. J., Welch M. J., Raichle M. E., Mintun M. A., Lich L. L., McGuire A. H., Zinn K. R., John E. K., Green M. A. Evaluation of a potential generator-produced PET tracer for cerebral perfusion imaging: single-pass cerebral extraction measurements and imaging with radiolabeled Cu-PTSM. J Nucl Med. 1990 Mar;31(3):351–359. [PubMed] [Google Scholar]
  15. Mathie R. T., Ralevic V., Alexander B., Burnstock G. Nitric oxide is the mediator of ATP-induced dilatation of the rabbit hepatic arterial vascular bed. Br J Pharmacol. 1991 Jun;103(2):1602–1606. doi: 10.1111/j.1476-5381.1991.tb09834.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Netti P. A., Baxter L. T., Boucher Y., Skalak R., Jain R. K. Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res. 1995 Nov 15;55(22):5451–5458. [PubMed] [Google Scholar]
  17. Netti P. A., Hamberg L. M., Babich J. W., Kierstead D., Graham W., Hunter G. J., Wolf G. L., Fischman A., Boucher Y., Jain R. K. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3137–3142. doi: 10.1073/pnas.96.6.3137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Rougier P. Are there indications for intraarterial hepatic chemotherapy or isolated liver perfusion? The case of liver metastases from colorectal cancer. Recent Results Cancer Res. 1998;147:3–12. doi: 10.1007/978-3-642-80460-1_1. [DOI] [PubMed] [Google Scholar]
  19. Sasaki Y., Imaoka S., Hasegawa Y., Nakano S., Ishikawa O., Ohigashi H., Taniguchi K., Koyama H., Iwanaga T., Terasawa T. Changes in distribution of hepatic blood flow induced by intra-arterial infusion of angiotensin II in human hepatic cancer. Cancer. 1985 Jan 15;55(2):311–316. doi: 10.1002/1097-0142(19850115)55:2<311::aid-cncr2820550202>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  20. Wallhaus T. R., Lacy J., Whang J., Green M. A., Nickles R. J., Stone C. K. Human biodistribution and dosimetry of the PET perfusion agent copper-62-PTSM. J Nucl Med. 1998 Nov;39(11):1958–1964. [PubMed] [Google Scholar]
  21. Zweit J., Goodall R., Cox M., Babich J. W., Potter G. A., Sharma H. L., Ott R. J. Development of a high performance zinc-62/copper-62 radionuclide generator for positron emission tomography. Eur J Nucl Med. 1992;19(6):418–425. doi: 10.1007/BF00177368. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES